143 related articles for article (PubMed ID: 35776149)
1. Comment on "Rebound hypercalcemia post-denosumab cessation in metastatic breast cancer": Waxing-Waning Serum Calcium following Denosumab use in a patient with Polyostotic Paget's Disease of Bone.
Pal R; Bhadada SK
Osteoporos Int; 2022 Oct; 33(10):2227-2228. PubMed ID: 35776149
[No Abstract] [Full Text] [Related]
2. Rebound hypercalcemia post-denosumab cessation in metastatic breast cancer.
Wang R; Renouf DA
Osteoporos Int; 2022 Jul; 33(7):1625-1629. PubMed ID: 35286436
[TBL] [Abstract][Full Text] [Related]
3. Incidence of Post-denosumab Rebound Hypercalcaemia in Bony-Metastatic Breast Cancer.
Wang R; Rajanayagam S; Ngan J; Renouf DA
Calcif Tissue Int; 2022 Oct; 111(4):391-395. PubMed ID: 35809111
[TBL] [Abstract][Full Text] [Related]
4. [Paget's disease and hypercalcemia: coincidence or causal relationship?].
Green I; Altman A
Harefuah; 2009 Oct; 148(10):708-10, 733. PubMed ID: 20073401
[TBL] [Abstract][Full Text] [Related]
5. Denosumab-induced severe hypocalcemia in a patient with Paget's disease of bone and impaired renal function.
Kostine M; Mehsen-Cetre N; Bannwarth B
Therapie; 2017 Jun; 72(3):383-385. PubMed ID: 27745697
[No Abstract] [Full Text] [Related]
6. Tumor-associated Hypercalcemia in a patient with Paget's disease.
Hung HC; Ou HY; Huang JS; Chuang MC; Wu TJ
Kaohsiung J Med Sci; 2008 Mar; 24(3):152-6. PubMed ID: 18364276
[TBL] [Abstract][Full Text] [Related]
7. Treatment of Paget's Disease of Bone with Denosumab: Case Report and Literature Review.
Reid IR; Sharma S; Kalluru R; Eagleton C
Calcif Tissue Int; 2016 Sep; 99(3):322-5. PubMed ID: 27193832
[TBL] [Abstract][Full Text] [Related]
8. Effects of intravenous etidronate disodium on skeletal and calcium metabolism.
Kanis JA; Urwin GH; Gray RE; Beneton MN; McCloskey EV; Hamdy NA; Murray SA
Am J Med; 1987 Feb; 82(2A):55-70. PubMed ID: 3103437
[TBL] [Abstract][Full Text] [Related]
9. Effect of dichloromethylene diphosphonate in Paget's disease of bone and in hypercalcaemia due to primary hyperparathyroidism or malignant disease.
Douglas DL; Duckworth T; Russell RG; Kanis JA; Preston CJ; Preston FE; Prenton MA; Woodhead JS
Lancet; 1980 May; 1(8177):1043-7. PubMed ID: 6103389
[TBL] [Abstract][Full Text] [Related]
10. Elevated levels of circulating fibroblast growth factor 23 with hypercalcemia following discontinuation of denosumab.
Uchida T; Yamaguchi H; Kushima C; Yonekawa T; Nakazato M
Endocr J; 2020 Jan; 67(1):31-35. PubMed ID: 31527321
[TBL] [Abstract][Full Text] [Related]
11. Denosumab in hypercalcemia of malignancy: a case series.
Dietzek A; Connelly K; Cotugno M; Bartel S; McDonnell AM
J Oncol Pharm Pract; 2015 Apr; 21(2):143-7. PubMed ID: 24415364
[TBL] [Abstract][Full Text] [Related]
12. Mithramycin in Paget's disease with superimposed hyperparathyroidism.
Veldhuis JD
Lancet; 1978 May; 1(8074):1152-3. PubMed ID: 77441
[No Abstract] [Full Text] [Related]
13. Intravenous disodium etidronate therapy in Paget's disease of bone and hypercalcemia of malignancy. Effects on biochemical parameters and bone histomorphometry.
Meunier PJ; Chapuy MC; Delmas P; Charhon S; Edouard C; Arlot M
Am J Med; 1987 Feb; 82(2A):71-8. PubMed ID: 3103438
[TBL] [Abstract][Full Text] [Related]
14. Hypercalcaemia in Paget's disease of bone.
Auld WH; Simpson RH; Smyth M
Lancet; 1979 Mar; 1(8115):562-3. PubMed ID: 85157
[No Abstract] [Full Text] [Related]
15. Osteonecrosis of the Jaw and Rebound Hypercalcemia in Young People Treated With Denosumab for Giant Cell Tumor of Bone.
Uday S; Gaston CL; Rogers L; Parry M; Joffe J; Pearson J; Sutton D; Grimer R; Högler W
J Clin Endocrinol Metab; 2018 Feb; 103(2):596-603. PubMed ID: 29211870
[TBL] [Abstract][Full Text] [Related]
16. Severe hypocalcemia following bisphosphonate treatment in a patient with Paget's disease of bone.
Whitson HE; Lobaugh B; Lyles KW
Bone; 2006 Oct; 39(4):954-8. PubMed ID: 16769264
[TBL] [Abstract][Full Text] [Related]
17. Paget's disease of the bone after treatment with Denosumab: a case report.
Schwarz P; Rasmussen AQ; Kvist TM; Andersen UB; Jørgensen NR
Bone; 2012 May; 50(5):1023-5. PubMed ID: 22586699
[TBL] [Abstract][Full Text] [Related]
18. Pamidronate. A review of its use in the management of osteolytic bone metastases, tumour-induced hypercalcaemia and Paget's disease of bone.
Coukell AJ; Markham A
Drugs Aging; 1998 Feb; 12(2):149-68. PubMed ID: 9509293
[TBL] [Abstract][Full Text] [Related]
19. Severe hypercalcemia following denosumab treatment in a juvenile patient.
Setsu N; Kobayashi E; Asano N; Yasui N; Kawamoto H; Kawai A; Horiuchi K
J Bone Miner Metab; 2016 Jan; 34(1):118-22. PubMed ID: 26056018
[TBL] [Abstract][Full Text] [Related]
20. Treatment of Paget's disease with hypercalcemia.
Gutteridge DH
Bone; 2006 Sep; 39(3):668. PubMed ID: 16798128
[No Abstract] [Full Text] [Related]
[Next] [New Search]
